Novo Nordisk AS (NVO) reports strong financial performance with a 24% sales increase, driven by demand for diabetes and ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Novo Nordisk reported forecast-beating third-quarter sales of its popular Wegovy weight-loss drug on Wednesday, reassuring ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

The company narrowed its full-year guidance as its blockbuster weight-loss drug soars in popularity.

Novo Nordisk A/S shares rose as surging sales of the blockbuster weight-loss treatment Wegovy reassured investors after rival ...

Novo Nordisk reported mixed Q3 earnings, but GLP-1 drugs contributed to revenue strength. The company also adjusted its ...

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Danish pharma giant Novo Nordisk has said it is aware of at least 10 deaths and 100 hospitalisations linked to compounded versions of semaglutide -- the active ingredient in popular diabetes and ...

Novo Nordisk (NVO) has released an update. Novo Nordisk reported an impressive 23% increase in sales to DKK 204.7 billion for the first nine ...